Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
作者信息
Levine Glenn N, D'Amico Anthony V, Berger Peter, Clark Peter E, Eckel Robert H, Keating Nancy L, Milani Richard V, Sagalowsky Arthur I, Smith Matthew R, Zakai Neil
出版信息
Circulation. 2010 Feb 16;121(6):833-40. doi: 10.1161/CIRCULATIONAHA.109.192695. Epub 2010 Feb 1.
Abstract
摘要
相似文献
1
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.前列腺癌中的雄激素剥夺疗法与心血管风险：美国心脏协会、美国癌症协会和美国泌尿外科学会的科学咨询意见：得到美国放射肿瘤学会认可
Circulation. 2010 Feb 16;121(6):833-40. doi: 10.1161/CIRCULATIONAHA.109.192695. Epub 2010 Feb 1.
2
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.前列腺癌的雄激素剥夺治疗与心血管风险：美国心脏协会、美国癌症协会和美国泌尿外科学会的科学咨询意见：得到美国放射肿瘤学会认可
CA Cancer J Clin. 2010 May-Jun;60(3):194-201. doi: 10.3322/caac.20061. Epub 2010 Feb 2.
3
Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.促性腺激素释放激素激动剂与前列腺癌男性 2 型糖尿病和心血管疾病风险
Drugs. 2011 Feb 12;71(3):255-61. doi: 10.2165/11588930-000000000-00000.
4
Long term androgen deprivation therapy in prostate cancer.前列腺癌的长期雄激素剥夺治疗
BMJ. 2008 Sep 22;337:a1361. doi: 10.1136/bmj.a1361.
5
Androgen deprivation therapy and cardiovascular risk.雄激素剥夺治疗与心血管风险。
Practitioner. 2015 Sep;259(1785):5.
6
Androgen deprivation therapy and cardiovascular complications.雄激素剥夺治疗与心血管并发症
Bratisl Lek Listy. 2016;117(10):557-561. doi: 10.4149/BLL_2016_109.
7
[Cardiovascular risks of androgen deprivation therapy for prostate cancer].[雄激素剥夺疗法治疗前列腺癌的心血管风险]
Urologe A. 2016 May;55(5):627-31. doi: 10.1007/s00120-015-0021-1.
8
Androgen deprivation therapy for prostate cancer.前列腺癌的雄激素剥夺疗法。
J Urol. 2007 Oct;178(4 Pt 1):1148. doi: 10.1016/j.juro.2007.07.066. Epub 2007 Aug 14.
9
Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.前列腺癌合并心血管疾病患者的雄激素剥夺治疗方法
Curr Urol Rep. 2017 Jun;18(6):41. doi: 10.1007/s11934-017-0688-5.
10
Androgen deprivation therapy for prostate cancer: new concepts and concerns.前列腺癌的雄激素剥夺治疗：新概念与新问题
Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):247-54. doi: 10.1097/MED.0b013e32814db88c.
引用本文的文献
1
Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort.在“我们所有人”研究项目队列的前列腺癌患者中，激素治疗的使用与不良心血管事件相关。
Prostate. 2025 Sep;85(12):1077-1086. doi: 10.1002/pros.24913. Epub 2025 Jun 11.
2
Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter study.立体定向体部放疗用于肺寡转移前列腺癌：一项国际回顾性多中心研究。
Clin Transl Radiat Oncol. 2025 Mar 10;52:100944. doi: 10.1016/j.ctro.2025.100944. eCollection 2025 May.
3
Addressing cardiovascular risks with a goal to prevent cardiovascular complications in patients undergoing antihormonal therapy for prostate cancer.针对心血管风险，目标是预防接受前列腺癌抗激素治疗患者的心血管并发症。
Cardiooncology. 2025 Mar 29;11(1):31. doi: 10.1186/s40959-025-00318-5.
4
Disparities in Cancer and Cardiovascular Disease Mortality Among Asian Americans Diagnosed with Urologic Cancer.被诊断患有泌尿系统癌症的亚裔美国人在癌症和心血管疾病死亡率方面的差异。
J Racial Ethn Health Disparities. 2025 Mar 11. doi: 10.1007/s40615-025-02354-4.
5
Assessing the effects of prostate cancer therapies on cardiovascular health.评估前列腺癌治疗对心血管健康的影响。
Nat Rev Urol. 2025 Feb 26. doi: 10.1038/s41585-025-01002-0.
6
Thrombo-inflammation linking androgen suppression with cardiovascular risk in patients with prostate cancer.血栓炎症将雄激素抑制与前列腺癌患者的心血管风险联系起来。
Cardiooncology. 2024 Dec 5;10(1):87. doi: 10.1186/s40959-024-00278-2.
7
The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.雄激素剥夺疗法对晚期前列腺癌患者心血管系统的影响。
Medicina (Kaunas). 2024 Oct 22;60(11):1727. doi: 10.3390/medicina60111727.
8
Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies.前列腺癌中心血管疾病综述：流行病学、危险因素、治疗方法及预防策略
Prostate Cancer Prostatic Dis. 2024 Nov 6. doi: 10.1038/s41391-024-00897-x.
9
A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer.地加瑞克与促性腺激素释放激素激动剂治疗前列腺癌的心血管疾病风险的系统评价和荟萃分析。
Clin Transl Oncol. 2025 Jun;27(6):2679-2688. doi: 10.1007/s12094-024-03772-2. Epub 2024 Nov 5.
10
Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer.雄激素受体转录激活结构域抑制剂作为前列腺癌的治疗方法。
Steroids. 2024 Oct;210:109482. doi: 10.1016/j.steroids.2024.109482. Epub 2024 Jul 23.
本文引用的文献
1
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.激素疗法用于患有冠状动脉疾病引起的充血性心力衰竭或心肌梗死的男性前列腺癌患者及死亡率。
JAMA. 2009 Aug 26;302(8):866-73. doi: 10.1001/jama.2009.1137.
2
Duration of androgen suppression in the treatment of prostate cancer.雄激素抑制在前列腺癌治疗中的持续时间。
N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095.
3
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.雄激素剥夺疗法对心血管疾病和糖尿病的影响。
J Clin Oncol. 2009 Jul 20;27(21):3452-8. doi: 10.1200/JCO.2008.20.0923. Epub 2009 Jun 8.
4
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.局部晚期前列腺癌雄激素剥夺治疗后的心血管死亡率：放射治疗肿瘤学组85-31研究
J Clin Oncol. 2009 Jan 1;27(1):92-9. doi: 10.1200/JCO.2007.12.3752. Epub 2008 Dec 1.
5
Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer.新诊断的局限性或复发性前列腺癌接受雄激素抑制治疗男性的死亡原因。
Cancer. 2008 Dec 15;113(12):3290-7. doi: 10.1002/cncr.23970.
6
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.放射肿瘤学组92 - 02方案的十年随访：局部晚期前列腺癌选择性雄激素剥夺持续时间的III期试验
J Clin Oncol. 2008 May 20;26(15):2497-504. doi: 10.1200/JCO.2007.14.9021. Epub 2008 Apr 14.
7
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.前列腺癌促性腺激素释放激素激动剂治疗期间的代谢变化：与经典代谢综合征的差异。
Cancer. 2008 May 15;112(10):2188-94. doi: 10.1002/cncr.23440.
8
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.前列腺癌联合雄激素阻断治疗期间的脂肪细胞因子、肥胖与胰岛素抵抗
Urology. 2008 Feb;71(2):318-22. doi: 10.1016/j.urology.2007.08.035.
9
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.局部晚期前列腺癌的心血管死亡率与雄激素剥夺治疗持续时间：放射治疗肿瘤学组92-02研究分析
Eur Urol. 2008 Oct;54(4):816-23. doi: 10.1016/j.eururo.2008.01.021. Epub 2008 Jan 15.
10
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.雄激素抑制联合放疗与单纯放疗治疗前列腺癌的随机试验
JAMA. 2008 Jan 23;299(3):289-95. doi: 10.1001/jama.299.3.289.
Zotero 插件